Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

PG. Richardson, SK. Kumar, T. Masszi, N. Grzasko, NJ. Bahlis, M. Hansson, L. Pour, I. Sandhu, P. Ganly, BW. Baker, SR. Jackson, AM. Stoppa, P. Gimsing, L. Garderet, C. Touzeau, FK. Buadi, JP. Laubach, M. Cavo, M. Darif, R. Labotka, D. Berg, P. Moreau

. 2021 ; 39 (22) : 2430-2442. [pub] 20210611

Language English Country United States

Document type Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc22004006

PURPOSE: The double-blind, placebo-controlled, phase III TOURMALINE-MM1 study demonstrated a statistically significant improvement in progression-free survival with ixazomib-lenalidomide-dexamethasone (ixazomib-Rd) versus placebo-Rd in patients with relapsed or refractory multiple myeloma. We report the final analyses for overall survival (OS). PATIENTS AND METHODS: Patients were randomly assigned to ixazomib-Rd (n = 360) or placebo-Rd (n = 362), stratified by number of prior therapies (1 v 2 or 3), previous proteasome inhibitor (PI) exposure (yes v no), and International Staging System disease stage (I or II v III). OS (intent-to-treat population) was a key secondary end point. RESULTS: With a median follow-up of 85 months, median OS with ixazomib-Rd versus placebo-Rd was 53.6 versus 51.6 months (hazard ratio, 0.939; P = .495). Lower hazard ratios, indicating larger magnitude of OS benefit with ixazomib-Rd versus placebo-Rd, were seen in predefined subgroups: refractory to any (0.794) or last (0.742) treatment line; age > 65-75 years (0.757); International Staging System stage III (0.779); 2/3 prior therapies (0.845); high-risk cytogenetics (0.870); and high-risk cytogenetics and/or 1q21 amplification (0.862). Following ixazomib-Rd versus placebo-Rd, 71.7% versus 69.9% of patients received ≥ 1 anticancer therapy, of whom 24.7% versus 33.9% received daratumumab and 71.8% versus 76.9% received PIs (next-line therapy: 47.5% v 55.8%). Rates of new primary malignancies were similar with ixazomib-Rd (10.3%) and placebo-Rd (11.9%). There were no new or additional safety concerns. CONCLUSION: Median OS values in both arms were the longest reported in phase III studies of Rd-based triplets in relapsed or refractory multiple myeloma at the time of this analysis; progression-free survival benefit with ixazomib-Rd versus placebo-Rd did not translate into a statistically significant OS benefit on intent-to-treat analysis. OS benefit was greater in subgroups with adverse prognostic factors. OS interpretation was confounded by imbalances in subsequent therapies received, especially PIs and daratumumab.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22004006
003      
CZ-PrNML
005      
20220127145638.0
007      
ta
008      
220113s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1200/JCO.21.00972 $2 doi
035    __
$a (PubMed)34111952
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Richardson, Paul G $u Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
245    10
$a Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma / $c PG. Richardson, SK. Kumar, T. Masszi, N. Grzasko, NJ. Bahlis, M. Hansson, L. Pour, I. Sandhu, P. Ganly, BW. Baker, SR. Jackson, AM. Stoppa, P. Gimsing, L. Garderet, C. Touzeau, FK. Buadi, JP. Laubach, M. Cavo, M. Darif, R. Labotka, D. Berg, P. Moreau
520    9_
$a PURPOSE: The double-blind, placebo-controlled, phase III TOURMALINE-MM1 study demonstrated a statistically significant improvement in progression-free survival with ixazomib-lenalidomide-dexamethasone (ixazomib-Rd) versus placebo-Rd in patients with relapsed or refractory multiple myeloma. We report the final analyses for overall survival (OS). PATIENTS AND METHODS: Patients were randomly assigned to ixazomib-Rd (n = 360) or placebo-Rd (n = 362), stratified by number of prior therapies (1 v 2 or 3), previous proteasome inhibitor (PI) exposure (yes v no), and International Staging System disease stage (I or II v III). OS (intent-to-treat population) was a key secondary end point. RESULTS: With a median follow-up of 85 months, median OS with ixazomib-Rd versus placebo-Rd was 53.6 versus 51.6 months (hazard ratio, 0.939; P = .495). Lower hazard ratios, indicating larger magnitude of OS benefit with ixazomib-Rd versus placebo-Rd, were seen in predefined subgroups: refractory to any (0.794) or last (0.742) treatment line; age > 65-75 years (0.757); International Staging System stage III (0.779); 2/3 prior therapies (0.845); high-risk cytogenetics (0.870); and high-risk cytogenetics and/or 1q21 amplification (0.862). Following ixazomib-Rd versus placebo-Rd, 71.7% versus 69.9% of patients received ≥ 1 anticancer therapy, of whom 24.7% versus 33.9% received daratumumab and 71.8% versus 76.9% received PIs (next-line therapy: 47.5% v 55.8%). Rates of new primary malignancies were similar with ixazomib-Rd (10.3%) and placebo-Rd (11.9%). There were no new or additional safety concerns. CONCLUSION: Median OS values in both arms were the longest reported in phase III studies of Rd-based triplets in relapsed or refractory multiple myeloma at the time of this analysis; progression-free survival benefit with ixazomib-Rd versus placebo-Rd did not translate into a statistically significant OS benefit on intent-to-treat analysis. OS benefit was greater in subgroups with adverse prognostic factors. OS interpretation was confounded by imbalances in subsequent therapies received, especially PIs and daratumumab.
650    _2
$a senioři $7 D000368
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $x terapeutické užití $7 D000971
650    _2
$a sloučeniny boru $x aplikace a dávkování $x škodlivé účinky $7 D001896
650    _2
$a dexamethason $x aplikace a dávkování $x škodlivé účinky $7 D003907
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a glycin $x aplikace a dávkování $x škodlivé účinky $x analogy a deriváty $7 D005998
650    _2
$a lidé $7 D006801
650    _2
$a lenalidomid $x aplikace a dávkování $x škodlivé účinky $7 D000077269
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mnohočetný myelom $x farmakoterapie $x mortalita $x patologie $7 D009101
650    _2
$a staging nádorů $7 D009367
650    _2
$a kvalita života $7 D011788
650    _2
$a analýza přežití $7 D016019
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kumar, Shaji K $u Division of Hematology, Mayo Clinic, Rochester, MN
700    1_
$a Masszi, Tamás $u 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary
700    1_
$a Grzasko, Norbert $u Department of Experimental Haematooncology, Medical University of Lublin, Lublin, Poland $u Center of Oncology of the Lublin Region St Jana z Dukli, Lublin, Poland
700    1_
$a Bahlis, Nizar J $u Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Canada
700    1_
$a Hansson, Markus $u Department of Hematology, Skåne University Hospital, Lund, Sweden $u Sahlgrenska Academy, Göteborg, Sweden
700    1_
$a Pour, Luděk $u Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Sandhu, Irwindeep $u Cross Cancer Institute, University of Alberta, Edmonton, Canada
700    1_
$a Ganly, Peter $u Department of Haematology, Christchurch Hospital, Christchurch, New Zealand
700    1_
$a Baker, Bartrum W $u Department of Haematology, Palmerston North Hospital, Palmerston North, New Zealand
700    1_
$a Jackson, Sharon R $u Department of Haematology, Middlemore Hospital, Auckland, New Zealand
700    1_
$a Stoppa, Anne-Marie $u Department of Hematology, Institut Paoli-Calmettes, Marseille, France
700    1_
$a Gimsing, Peter $u Department of Hematology, University Hospital Rigshospitalet, Copenhagen, Denmark
700    1_
$a Garderet, Laurent $u Hôpital Pitié-Salpêtrière, Paris, France
700    1_
$a Touzeau, Cyrille $u University Hospital Hôtel Dieu, Nantes, France
700    1_
$a Buadi, Francis K $u Division of Hematology, Mayo Clinic, Rochester, MN
700    1_
$a Laubach, Jacob P $u Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
700    1_
$a Cavo, Michele $u IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy
700    1_
$a Darif, Mohamed $u Millennium Pharmaceuticals Inc, Cambridge, MA
700    1_
$a Labotka, Richard $u Millennium Pharmaceuticals Inc, Cambridge, MA
700    1_
$a Berg, Deborah $u Millennium Pharmaceuticals Inc, Cambridge, MA
700    1_
$a Moreau, Philippe $u University Hospital Hôtel Dieu, Nantes, France
773    0_
$w MED00002596 $t Journal of clinical oncology : official journal of the American Society of Clinical Oncology $x 1527-7755 $g Roč. 39, č. 22 (2021), s. 2430-2442
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34111952 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127145634 $b ABA008
999    __
$a ok $b bmc $g 1751463 $s 1155155
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 39 $c 22 $d 2430-2442 $e 20210611 $i 1527-7755 $m Journal of clinical oncology $n J. clin. Oncol. $x MED00002596
LZP    __
$a Pubmed-20220113

Find record

Citation metrics

Archiving options